[Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-psp) typically presents with the classic Richardson syndrome, but increasing evidence demonstrates a prolonged prodromal phase with subtle but identifiable premotor features. Early detection is crucial for timely intervention, clinical trial enrollment, and patient counseling.
[Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-psp) typically presents with the classic Richardson syndrome, but increasing evidence demonstrates a prolonged prodromal phase with subtle but identifiable premotor features. Early detection is crucial for timely intervention, clinical trial enrollment, and patient counseling.
The prodromal phase of PSP encompasses the period before the emergence of the classic vertical supranuclear gaze palsy and postural instability. This phase can last from 2 to 10 years and is characterized by non-specific symptoms that overlap with other neurodegenerative conditions, making early diagnosis challenging. Research from the last decade has identified several clinical, imaging, and biochemical markers that can help identify individuals in the prodromal stage["@mandelstam2024"][@davis2024].
The earliest manifestations of PSP often precede the classic syndrome by years. Patients may present with subtle changes in gait and balance, with frequent falls becoming apparent as early as 2-3 years before diagnosis. These falls typically occur early and are often unexplained, distinguishing PSP from Parkinson's disease where falls usually occur later in disease progression.
A characteristic early feature is progressive axial rigidity, particularly affecting the neck and trunk. Patients may notice increasing difficulty turning their head and experience stiffness in the neck muscles. This is often accompanied by a change in posture, with the development of a forward-flexed or extended posture that differs from the typical flexed posture seen in Parkinson's disease.
Advanced video-oculography (VOG) has revealed subtle ocular motor deficits in prodromal PSP that precede clinically evident gaze palsy[@johansson2024]:
Rapid eye movement sleep behavior disorder (RBD) has emerged as an important early marker in PSP, present in approximately 30-50% of patients in the prodromal phase. RBD manifests as acting out dreams during REM sleep, which can precede motor symptoms by years. The presence of RBD, particularly in combination with other features, may indicate an underlying 4R tauopathy[@wilson2024].
Other sleep disturbances in the prodromal phase include insomnia, sleep fragmentation, and excessive daytime sleepiness. Circadian rhythm disturbances have also been documented, with alterations in body temperature regulation and hormonal circadian patterns.
Subtle cognitive changes may appear before motor symptoms, with executive dysfunction being most prominent. Patients may notice difficulties with planning, organization, and multitasking. Reduced verbal fluency and slowed processing speed can be detected on neuropsychological testing even in the premotor phase.
Psychiatric manifestations in the prodromal phase include apathy, which is highly prevalent and may be one of the earliest features. Depression and anxiety can also occur but are less specific. Personality changes, including reduced empathy and disinhibition, may be noted by family members.
Even before the classic vertical supranuclear gaze palsy develops, subtle ocular motor abnormalities can be detected. Square wave jerks, small involuntary saccadic intrusions during fixation, are common in the prodromal phase. Decreased saccadic velocity, particularly for vertical saccades, can be measured using video-oculography and may precede clinically evident gaze palsy.
Blinking abnormalities, including reduced blink rate and increased blink latency, have been documented. These subtle signs can be detected using standardized eye movement recordings and may provide early diagnostic clues.
Advanced MRI techniques reveal changes in prodromal PSP that precede clinical diagnosis. Regional brain atrophy, particularly in the midbrain, superior cerebellar peduncle, and frontal regions, can be detected. The "hummingbird sign" on midsagittal T1-weighted images, while characteristic of established PSP, may be partially visible in the prodromal phase.
Midbrain atrophy metrics, including the midbrain area and the PSP rating scale midbrain score, show progressive decline even before clinical diagnosis. Atrophy of the superior cerebellar peduncle is another early marker, visible on diffusion-weighted imaging. Studies using volumetric MRI have shown that midbrain volume loss can be detected up to 5 years before clinical diagnosis.
| Region | Atrophy detectable | Sensitivity | Specificity vs PD |
|--------|-------------------|-------------|-------------------|
| Midbrain | 4-5 years pre-diagnosis | 72% | 85% |
| Superior cerebellar peduncle | 3-4 years pre-diagnosis | 68% | 80% |
| Frontal cortex | 2-3 years pre-diagnosis | 60% | 75% |
| Subthalamic nucleus | 3-4 years pre-diagnosis | 65% | 78% |
DTI measures of white matter integrity show early changes in prodromal PSP. Reduced fractional anisotropy and increased mean diffusivity in the superior cerebellar peduncle, midbrain, and frontal white matter are characteristic. These changes reflect early axonal loss and can help distinguish prodromal PSP from other parkinsonian syndromes.
Tau PET imaging using radiotracers like ^18F-AV-1451 (flortaucipir) shows increased binding in the basal ganglia and brainstem of PSP patients[@brown2025]. While typically positive in established disease, emerging evidence suggests that subtle increases in tau deposition may be detectable in the prodromal phase, particularly in the substantia nigra and brainstem structures.
Recent longitudinal tau PET studies have shown that flortaucipir SUVR increases in the globus pallidus, subthalamic nucleus, and midbrain at rates of 3-5% per year in prodromal PSP subjects, compared to 1-2% per year in healthy controls.
CSF total tau and phosphorylated tau (p-tau181, p-tau217) levels are elevated in PSP compared to healthy controls, but the magnitude of elevation is less pronounced in the prodromal phase[@jones2025]. Emerging evidence suggests that neurofilament light chain (NfL) in CSF and blood may serve as a marker of disease progression even in early stages[@suzuki2024].
Tau oligomers and tau fragments in CSF are being investigated as more specific markers of early tau pathology. Research from 2025 suggests that p-tau217 shows superior discrimination between prodromal PSP and healthy controls compared to p-tau181, with an AUC of 0.92[@chen2025].
Neurofilament light chain (NfL) in both CSF and blood shows promise as a marker of neuronal injury in PSP. Elevated NfL levels can be detected in the prodromal phase and correlate with disease progression. Similarly, neurogranin, a marker of synaptic dysfunction, may be elevated. Serum NfL in prodromal PSP shows a median of 45 pg/mL compared to 18 pg/mL in controls, with 85% sensitivity at 80% specificity for detecting prodromal disease[@suzuki2024].
CSF and blood inflammatory markers, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and YKL-40, show altered levels in PSP[@miller2025]. These changes may be present early in the disease course and reflect ongoing neuroinflammation. Elevated YKL-40 (chitinase-3-like protein 1) reflects microglial activation and has been shown to correlate with disease progression in prodromal PSP.
The H1 haplotype of the [MAPT](/genes/mapt) gene is the strongest genetic risk factor for PSP[@kim2024]. Subhaplotypes within H1, particularly H1c, are associated with increased risk. However, the presence of risk alleles does not predict the timing of disease onset, and the penetrance is incomplete.
Other genetic variants, including those in the C9orf72 gene and NFASC, have been associated with increased PSP risk but with smaller effect sizes. Genetic testing is not routinely recommended but may be considered in cases with early onset or family history.
While no definitive environmental risk factors have been established, some associations have been proposed. Rural living, well water consumption, and exposure to certain industrial chemicals have been studied but with inconsistent results. The role of traumatic brain injury remains controversial.
Recent advances in machine learning have enabled probabilistic prediction of PSP conversion from prodromal features[@patel2025].
| Model Type | Features | Accuracy | AUC |
|------------|----------|----------|-----|
| Random Forest | Clinical + MRI + CSF | 85% | 0.91 |
| Gradient Boosting | Eye tracking + genetic | 82% | 0.89 |
| Neural Network | Multimodal (all markers) | 88% | 0.94 |
| SVM | Fluid biomarkers alone | 75% | 0.83 |
The most influential features for predicting conversion to clinically definite PSP include:
Ensemble models combining clinical, imaging, fluid, and genetic data achieve the highest predictive accuracy, with positive predictive values of 85-90% when multiple modalities are incorporated.
Optical coherence tomography (OCT) studies have revealed retinal abnormalities in prodromal PSP[@tanaka2025]:
Distinguishing prodromal PSP from other conditions is challenging due to symptom overlap. The differential includes:
Early diagnosis of PSP in the prodromal phase has several implications. It allows for better prognostic counseling, enabling patients and families to plan for future needs. Early diagnosis also provides the opportunity to enroll patients in clinical trials targeting disease-modifying therapies, which may be more effective when initiated earlier in the disease course.
While no disease-modifying therapy exists for PSP, early intervention with symptomatic treatments may improve quality of life. Physical therapy for balance and gait training, speech therapy for dysarthria, and treatment of neuropsychiatric symptoms can be initiated in the prodromal phase.
Patients identified as prodromal PSP should be monitored regularly for progression to clinically definite PSP. Regular assessment of gait, balance, ocular motor function, and cognitive status is recommended. Neuroimaging and fluid biomarkers may be used to track disease progression in research settings.
The identification of prodromal features in PSP represents a significant advance in understanding disease progression and may facilitate early diagnosis and intervention. While challenges remain in distinguishing prodromal PSP from other neurodegenerative conditions, the combination of clinical features, neuroimaging markers, and fluid biomarkers is improving diagnostic accuracy. Ongoing research aims to develop more sensitive and specific markers for early detection and to identify therapeutic targets that may be most effective when initiated early in the disease course.
The following diagram shows the key molecular relationships involving PSP Prodromal Features and Early Detection discovered through SciDEX knowledge graph analysis: